July 3, 2008 - Boston Scientific Corp. today said the FDA has approved the PROMUS Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease.
The PROMUS Stent is a private-labeled XIENCE V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific under an agreement executed prior to the 2006 acquisition of the former Guidant Corp. by Boston Scientific. FDA approval clears the way for Boston Scientific to launch the PROMUS Stent immediately in the U.S.
